GRAL
Q2 wasn’t just talk
GRAIL’s second-quarter call had the usual earnings-show sparkle, but the real headline was the combo platter: revenue climbed 26% year over year to $44.7 million, Galleri test volumes rose 35%, and management said the business is still gaining traction where it matters most — actual usage.
The Samsung money matters
The company also said it completed a $110 million financing round with Samsung. That’s not pocket change, and it gives GRAIL more runway to push international expansion, especially in South Korea, Japan, and Singapore. If you’re looking for the corporate version of “don’t put all your eggs in one basket,” this is it.
FDA watch is still the main event
The bigger long-term catalyst is still regulatory. GRAIL said it continues to pursue FDA approval for Galleri, expects an advisory committee meeting in the fall, and is aiming for approval in early 2027. That means the stock still lives and dies by the slow-burn drama of the FDA process — thrilling, if your idea of fun involves calendars and acronyms.
Why investors should care
The bull case is pretty simple:
- more test volume
- better clinical validation
- fresh capital to keep expanding overseas
- a potential FDA unlock that could widen the market
The company also leaned hard into its clinical edge, pointing to large studies and a very low false positive rate. Translation: GRAIL wants to be the adult in the room while competitors are still showing up with science projects.
Big picture: this was a “steady progress, still waiting for the big yes” kind of quarter. The business is growing, the balance sheet got a boost, and the FDA overhang remains the giant doorstop in the room.